The Fort Worth Press - MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology

The article, titled "KETAMIR-2, A NEW MOLECULAR ENTITY AND NOVEL KETAMINE ANALOG," authored by Itzchak Angel, Ph.D., MIRA's Chief Scientific Advisor, highlights Ketamir-2's pharmacological differentiation from ketamine and its potential as a next-generation CNS therapeutic.

Peer Review Validates Differentiated Pharmacology and Safety

Acceptance into Frontiers in Pharmacology provides external scientific validation by independent experts, underscoring the rigor and credibility of MIRA's research. The publication confirms that Ketamir-2 was specifically engineered to overcome limitations associated with ketamine-such as poor oral bioavailability, dissociative side effects, and non-specific receptor binding.

Key Highlights from the Publication:

• Highly Selective, Cleaner Mechanism: Ketamir-2 is a low-affinity NMDA receptor antagonist that selectively targets the NMDA PCP site. Unlike ketamine, Ketamir-2 showed no significant interaction with over 40 other receptors, transporters, or ion channel targets-including dopamine, opioid, serotonin, and monoaminergic systems-highlighting its clean pharmacological profile and reduced off-target effects.

• No Hyperlocomotion, Even at High Doses: In contrast to ketamine, Ketamir-2 did not induce hyperlocomotion in preclinical models-a behavior associated with agitation and schizophrenia-like symptoms-suggesting a favorable neurobehavioral safety profile.

• Demonstrated Antidepressant and Anxiolytic Activity: In validated behavioral models (Open Field Test, Elevated Plus Maze, Forced Swim Test), Ketamir-2 demonstrated clear anxiolytic and antidepressant-like effects. Ketamine, used as a control, either showed no benefit or limited effect in most tests.

• Oral Delivery with Efficient Brain Penetration: All studies were conducted via the oral route. Ketamir-2 was shown to cross the blood-brain barrier and is not a substrate for P-glycoprotein, which often limits oral drug delivery to the brain. This may explain Ketamir-2's ability to maintain CNS activity despite its lower NMDA receptor affinity.

"We are honored to see our foundational research on Ketamir-2 published in a high-impact scientific journal," said Erez Aminov, CEO of MIRA. "This milestone adds meaningful scientific credibility and supports our confidence in Ketamir-2's differentiated mechanism, favorable safety profile, and broad clinical potential."

"This peer-reviewed publication provides clear validation of the differentiated pharmacological profile of Ketamir-2," added Dr. Itzchak Angel, Chief Scientific Advisor. "Its clean pharmacological profile and safety make it a compelling next-generation alternative to ketamine."

Clinical and Corporate Updates

MIRA also announced that its Phase 1 trial of Ketamir-2 is progressing as planned, with no safety concerns reported to date and dose escalation advancing. The Company expects to initiate a Phase 2a clinical trial in neuropathic pain by year-end 2025, pending regulatory clearance.

In addition, the Company is preparing new scientific data submissions and presentations to further support Ketamir-2's clinical development and potential across CNS-related conditions.

MIRA also reaffirmed that the acquisition of SKNY Pharmaceuticals, which includes a first-in-class oral CB1/CB2 inverse agonist for obesity and smoking cessation (SKNY-1), is progressing on track. The Company has submitted the required regulatory filings for the merger to the U.S. Securities and Exchange Commission (SEC).

The publication will be available upon release at: www.frontiersin.org/journals/pharmacology

Cautionary Note Regarding Forward-Looking Statements

This press release and the statements of MIRA's management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and other SEC filings, which are on file with the SEC at www.sec.gov and MIRA's website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information

Helga Moya
[email protected]
(786) 432-9792

SOURCE: MIRA Pharmaceuticals

View the original press release on ACCESS Newswire

M.Delgado--TFWP